Adriamycin: comparison of a 5-week schedule with a 3-week schedule in the treatment of breast cancer

Knight, E.W.; Horton, J.; Cunningham, T.; Rhie, F.; Lagakos, S.; Rosenbaum, C.; Taylor, S.; Tennant, J.

Cancer Treatment Reports 63(1): 121-122

1979


ISSN/ISBN: 0361-5960
PMID: 369683
Document Number: 149714
Two adriamycin dose-schedules were compared using 36 patients. The 5 wk and 3 wk schedules appear to be equivalent in terms of remission induction and maintenance, toxicity and survival. If so, valuable time may be gained before cardiotoxicity (the usual limiting toxicity of adriamycin) sets in.

Document emailed within 1 workday
Secure & encrypted payments